Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate‐grade or high‐grade liposarcoma

• Published in: Cancer Vol. 123; no. 23; pp. 4640 - 4647
• Main Authors: Samuels, Brian L., Chawla, Sant P., Somaiah, Neeta, Staddon, Arthur P., Skubitz, Keith M., Milhem, Mohammed M., Kaiser, Pamela E., Portnoy, David C., Priebat, Dennis A., Walker, Mark S., Stepanski, Edward J.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01-12-2017
• Subjects: activity; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors - therapeutic use; Cancer; Complications; Confidence intervals; Diarrhea; Disease control; Enzyme inhibitors; Fatigue; Female; Follow-Up Studies; Humans; Hypertension; Inhibitor drugs; Inhibitors; Liposarcoma; Liposarcoma - drug therapy; Liposarcoma - pathology; Male; Metastases; Metastasis; Middle Aged; Nausea; Neoplasm Grading; Null hypothesis; Oncology; Patients; pazopanib; phase 2; Prospective Studies; Protein-tyrosine kinase; Pyrimidines - therapeutic use; Quality; Radiology; Sarcoma; Soft tissue sarcoma; Sulfonamides - therapeutic use; Survival; Survival Rate; Targeted cancer therapy; Tumors; Tyrosine; Vascular endothelial growth factor; Young Adult; phase 2; activity; pazopanib; soft tissue sarcoma; liposarcoma
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/cncr.30926

BACKGROUND
This phase 2, single‐arm, multicenter study was designed to determine the treatment activity and safety of single‐agent pazopanib in patients with unresectable or metastatic liposarcoma.
METHODS
Eligible patients had high‐grade or intermediate‐grade liposarcoma with measurable tumors that were unresectable or metastatic, documented disease progression, and had received any number of prior treatments, excluding previous treatment with a vascular endothelial growth factor inhibitor or a tyrosine kinase inhibitor. Patients received oral pazopanib 800 mg once daily for 28‐day cycles. Tumor response was evaluated by local radiology assessments every 3 cycles. The primary endpoint was the progression‐free rate (PFR) at 12 weeks (PFR12).
RESULTS
Forty‐one patients were enrolled. The PFR12 was 68.3% (95% confidence interval [CI], 51.9%‐81.9%), which was significantly greater than the null hypothesis value of 40% (P = .0002). At 24 weeks, 39% of patients (95% CI, 24.2%‐55.5%) remained progression free, and 44% experienced tumor control (partial response or stable disease). The median progression‐free survival was 4.4 months (95% CI, 3.2‐6.5 months), and the median overall survival was 12.6 months (95% CI, 8.5‐16.2 months). The most common adverse events overall were nausea (39%), hypertension (36.6%), diarrhea (34.1%), and fatigue (29.3%), which were typically less than grade 3. There were 5 deaths on study (12.2%), 3 of which were from possible complications of therapy.
CONCLUSIONS
The current study provides evidence of potential activity of pazopanib in the liposarcoma subset of patients with soft tissue sarcoma that was specifically excluded from the phase 3 PALETTE trial of other soft tissue sarcoma types. Cancer 2017;123:4640‐4647. © 2017 American Cancer Society.
This phase 2, multicenter, single‐arm study in patients with liposarcoma demonstrates that treatment with oral pazopanib 800 mg daily results in a 12‐week progression‐free rate of 68.3% (95% confidence interval, 51.9%‐81.9%) and thus provides evidence of potential activity for this soft tissue sarcoma subset, which was specifically excluded from the PALETTE trial of other soft tissue sarcoma types.